Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India
Top Cited Papers
Open Access
- 6 April 2018
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 4 (2), 46
- https://doi.org/10.3390/jof4020046
Abstract
Mucormycosis is an emerging opportunistic fungal infection. Increasing immunocompromization, widespread use of antibacterial and antifungal agents (such as voriconazole prophylaxis), carcinomas, transplantation and lifestyle diseases such as diabetes are the main contributors to this situation. The predominant clinical manifestations of mucormycosis vary from host to host, with rhino-orbital-cerebral, pulmonary, cutaneous, and gastrointestinal infections being the most common. In India, the prevalence of mucormycosis is approximately 0.14 cases/1000 population, which is about 70 times the worldwide-estimated rate for mucormycosis. The present study was undertaken over a period of five years (January 2009–December 2014) to determine the prevalence of mucormycosis. The samples suspected of mucormycosis were examined by direct KOH wet mount and cultured on Sabouraud’s dextrose agar without actidione and on blood agar as per standard mycological techniques. Histopathological correlation was done for most of the cases. Antifungal susceptibility testing was performed by the EUCAST reference method. We identified a total of 82 cases of mucormycosis out of a total of 6365 samples received for mycological culture and examination during the said time period. Out of these, 56 were male patients and 27 were females. Most common presentation was rhino-orbito-cerebral (37), followed by cutaneous (25), pulmonary (14), oral cavity involvement (4) and gastrointestinal (2). The most common risk factors were diabetes and intramuscular injections. The fungi isolated were Rhizopus arrhizus (17), Apophysomyces variabilis (12), R. microsporus (9), Lichtheimia ramosa (8), Saksenaea erythrospora (5), Syncephalastrum racemosus (4), R. homothallicus (2), Rhizomucor pusillus (1), Mucor irregularis (1) and A. elegans (1). The mainstay of the treatment was amphotericin B, along with extensive surgical debridement whenever feasible. Most of the patients (50) recovered, but 25 died. The rest of the patients left against medical advice. “Nip in the Bud” should be the mantra for clinicians/surgeons for a favorable prognosis. Early diagnosis, prompt institution of appropriate antifungal therapy, surgical debridement whenever necessary, knowledge of risk factors and their timely reversal is the key for management.Keywords
This publication has 21 references indexed in Scilit:
- Mucormycosis – from the pathogens to the diseaseClinical Microbiology & Infection, 2014
- Necrotizing Cutaneous Mucormycosis after a Tornado in Joplin, Missouri, in 2011The New England Journal of Medicine, 2012
- A significant number of reported Absidia corymbifera ( Lichtheimia corymbifera ) infections are caused by Lichtheimia ramosa (syn. Lichtheimia hongkongensis ): an emerging cause of mucormycosisEmerging Microbes & Infections, 2012
- Epidemiology and Clinical Manifestations of MucormycosisClinical Infectious Diseases, 2012
- Saksenaea erythrospora Infection following Combat TraumaJournal of Clinical Microbiology, 2011
- Chronic Rhinofacial Mucormycosis Caused by Mucor irregularis (Rhizomucor variabilis) in IndiaJournal of Clinical Microbiology, 2011
- Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia SpeciesClinical Microbiology Reviews, 2011
- Molecular Phylogeny and Proposal of Two New Species of the Emerging Pathogenic FungusSaksenaeaJournal of Clinical Microbiology, 2010
- Cavitary Pulmonary Zygomycosis Caused by Rhizopus homothallicusJournal of Clinical Microbiology, 2010
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005